Sign In
Buy HRTX
$0.447
-0.0032 (-0.711%)
At Close: Jun 03, 2026
Heron's Pain Management Drug Gets Complete Response Letter
03:15pm, Tuesday, 30'th Jun 2020
Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.
Heron Therapeutics: The Play Now
01:41pm, Tuesday, 30'th Jun 2020
The stock of Heron Therapeutics sold off hard in trading Monday after receiving an unexpected CRL from the FDA for HTX-011 for post operative pain. However, the
Kiniksa's Heart Drug, And Other News: The Good, Bad, And Ugly Of Biopharma
01:14pm, Tuesday, 30'th Jun 2020
Kiniksa's heart inflammation drug shows positive results. Heron's HTX-011 gets a CRL. SEGN's Tisotumab Vedotin reports positive data.
Cancer Therapeutics & Supportive Care Drugs Market Research Report by Drug Class (Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents, Granulocyte-Colony Stimulating Factors, and Nonsteroi
Xconomy: FDA Again Dings Heron’s Opioid Alternative Over “Nonclinical Issues”
09:39pm, Monday, 29'th Jun 2020
Heron Therapeutics revealed Monday that its investigational non-opioid drug for treating postoperative pain has again been rejected by the FDA. The San
So far Monday, June 29, NASDAQ is up 3.38% and the S&P is up 2.09%. Let’s take a look at
Why Pacira BioSciences Is Soaring Today | The Motley Fool
04:58pm, Monday, 29'th Jun 2020
Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.
Heron Therapeutics (HRTX) Initiated with a Buy at Stifel Nicolaus - Markets
03:44pm, Monday, 29'th Jun 2020
Stifel Nicolaus analyst Derek Archila initiated coverage with a Buy rating on Heron Therapeutics (HRTX – Research Report) today and
Why Heron Therapeutics Stock Is Tanking Today | The Motley Fool
03:25pm, Monday, 29'th Jun 2020
Its non-opioid painkiller gets a rejection over non-clinical issues.
U.S. FDA again declines to approve Heron Therapeutics' non-opioid painkiller
02:04pm, Monday, 29'th Jun 2020
Heron Therapeutics said on Monday the U.S. Food and Drug Administration has once again declined to approve its non-opioid painkiller for post-operative pain and sought more data, sending its shares do
Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options
12:47pm, Monday, 29'th Jun 2020
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
12:45pm, Monday, 29'th Jun 2020
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan
Heron Therapeutics Target of Unusually Large Options Trading (NASDAQ:HRTX)
11:10am, Monday, 29'th Jun 2020
Heron Therapeutics Inc (NASDAQ:HRTX) was the target of some unusual options trading activity on Monday. Stock traders purchased 6,991 call options on the company. This represents an increase of approx
So far Sunday, June 28, NASDAQ is down -9.25% and the S&P is down -6.11%. Here are this morning’s most
So far Saturday, June 27, NASDAQ is down -9.25% and the S&P is down -6.11%. Here are this morning’s most
